Table 1.

Characteristics of patients with breast cancer (n = 44). Comparison between recurrence and control patients was done.

Characteristic	Recurrence*	Control**	p-value
Patients, n (%)	22 (50%)	22 (50%)
Age at surgery (years)***	47 (29–63)	50 (35–75)	0.289
Tumor size (cm)***	3.3 (1.4–8.0)	2.6 (1.5–5.5)	0.044
Operation methods			0.203
Partial mastectomy and sentinel lymph node biopsy	1 (33%)	2 (67%)
Partial mastectomy and axillary lymph node dissection	1 (100%)	0
Total mastectomy and sentinel lymph node biopsy	2 (100%)	0
Modified radical mastectomy	18 (47%)	20 (53%)
Tumor-infiltrating lymphocytes
Low
High
Histology grade			>0.999
Nuclear grade II	4 (44%)	5 (56%)
Nuclear grade III	18 (51%)	17 (49%)
Extensive intraductal components	10 (67%)	5 (33%)	0.203
Lymphatic tumor emboli	13 (52%)	12 (48%)	>0.999
Extranodal extension	6 (67%)	3 (33%)	0.460
Tumor stage			0.493
T1	1 (33%)	2 (67%)
T2	18 (49%)	19 (51%)
T3	3 (75%)	1 (25%)
Nodal stage			0.103
N0	9 (47%)	10 (53%)
N1	6 (46%)	7 (54%)
N2	3 (38%)	5 (62%)
N3	4 (100%)	0
AJCC TNM stage			0.168
Stage IA	1 (33%)	2 (9%)
Stage IIA	7 (47%)	8 (53%)
Stage IIB	7 (50%)	7 (50%)
Stage IIIA	3 (37%)	5 (63%)
Stage IIIC	4 (100%)	0
Intrinsic subtypes			0.716
Luminal A	3 (37%)	5 (63%)
Luminal B without Her-2/Neu overexpression	3 (50%)	3 (50%)
Luminal B with Her-2/Neu overexpression	6 (67%)	3 (33%)
Her-2/Neu overexpression	3 (37%)	5 (63%)
Triple-negative breast cancer	7 (54%)	6 (46%)

AJCC TNM stage, American Joint Committee on Cancer tumor-node-metastases (TNM) staging system, 7^th ed.

^*Cancer recurrence within 24 months postoperatively. ^**No recurrence after 24 months postoperatively. ^***Values are expressed as median (range).